Khiron Announces Grants of Restricted Share Units
Khiron Life Sciences Corp. (KHRNF) announced the award of restricted share units (RSUs) to new and existing directors and an officer. On February 8, 2021, the board approved the grants as part of its amended RSU plan. A total of 888,298 shares were allocated, with specific vesting schedules: 425,532 shares to Director Juan Carlos Echeverry, 212,766 to Director Deborah Rosati, and 250,000 to CFO Joel Friedman. The company is a leader in medical cannabis in Latin America and is expanding operations in Europe, aiming for sales in Germany and Brazil in early 2021.
- Approval of RSUs may align management's interests with shareholder value.
- Expanding operations in Germany and Brazil could enhance revenue potential.
- None.
TORONTO, Feb. 9, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of restricted share units ("RSUs") under the Company's amended and restated restricted share unit plan approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.
On February 8, 2021, the board of directors approved a grant of RSUs to one new and one existing director, and a new officer of the Company, in accordance with the terms of the respective agreements between the Company and each individual, as set forth below.
Name | Title/Position | Number of Shares | Vesting Schedule |
Juan Carlos Echeverry | Director | 425,532 | RSUs will vest in thirds on each of the first, second and third anniversaries of the grant date |
Deborah Rosati | Director | 212,766 | RSUs will vest in thirds on each of the first, second and third anniversaries of the grant date |
Joel Friedman | CFO | 250,000 | 125,000 RSUs will vest as follows:
The remaining 125,000 RSUs will vest as follows:
|
TOTAL | 888,298 |
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-announces-grants-of-restricted-share-units-301225467.html
SOURCE Khiron Life Sciences Corp.
FAQ
What are the details of the RSUs granted on February 8, 2021 by Khiron Life Sciences Corp. (KHRNF)?
Who received RSUs in the recent announcement by Khiron Life Sciences Corp.?
How many RSUs did Khiron Life Sciences Corp. grant to its CFO?
What is the significance of the RSUs granted by Khiron Life Sciences Corp. for investors?
What markets is Khiron Life Sciences Corp. planning to enter in 2021?
